T H E UNITED STATES R E I Nstated vaccination against smallpox among military personnel in 2002 and among selected civilian groups in January 2003. Routine smallpox vaccination had been suspended among US civilians in 1973 and among military personnel in the late 1980s. Rare adverse events causally associated with smallpox vaccination include cutaneous, 1-4 ocular, [1] [2] [3] [4] [5] and neurologic [1] [2] [3] [4] 6, 7 syndromes. Acute neurologic disease occurs after many vaccinations, including smallpox vaccination. 6, 7 Central nervous system (CNS) and peripheral nervous system complications of smallpox vaccination are rare but severe vaccine-associated adverse events. The most common CNS complication after smallpox vaccination is encephalitis (postvaccinial encephalomyelitis [PVE]). 6 Other neurologic events have been associated temporally with smallpox vaccination. A recent assessment substantiates the frequency of postvaccinial headache. 8 Other neurologic syndromes infrequently historically reported in temporal association with smallpox vaccination include GuillainBarré syndrome (GBS), 9 acute cranial neuropathies, 10 poliomyelitis-like syndrome, 11 Bell palsy, 12 and transverse myelitis.
man Services (DHHS) and Department of Defense (DoD) smallpox vaccinees to characterize them clinically and assess their frequency. All vaccinations were done with the New York City Board of Health strain of vaccinia (Dryvax, Wyeth Pharmaceuticals, Pearl River, NY).
METHODS
The Smallpox Vaccine Adverse Events Monitoring and Response Activities (SVAEMRA) identified adverse events after smallpox vaccination through clinical consultation and reporting to the Vaccine Adverse Event Reporting System (VAERS).
A team of Centers for Disease Control and Prevention (CDC) SVAEMRA clinicians with expertise in smallpox vaccine-related safety responded to calls from health professionals identifying a We classified cases into categories according to the predominant complaint, sign, or symptom. When possible, we compared observed rates (number of reports per number of vaccinations) of neurologic syndromes among vaccinees to expected incidence rates in the general population.
Observations in this report are based on VAERS-associated surveillance and response activities, which are exempt from institutional review board review.
RESULTS
The SVAEMRA clinical team or DoD was consulted on 30 serious events (eg, resulting in hospitalization, disability, or death) temporally associated with smallpox vaccination events and features suggesting neurologic involvement. These 30 cases were actively investigated by the lead author. Twelve were neurologic, were also captured through VAERS report review, and are summarized in TABLE 1.
Between December 16, 2002, and March 11, 2004 , approximately 665 000 civilians and military personnel received smallpox vaccine, including approximately 435 000 primary (ie, first-time) vaccinees (66%). During this period, 2060 VAERS reports involving smallpox vaccine were received; 670 contained COSTART codes related to neurologic illness, 320 involved DHHS vaccinees (primarily civilian health care workers), and 350 involved DoD vaccinees (primarily military personnel deployed to overseas field situations). A preliminary screen excluded 456 reports unrelated to neurologic illness; the remaining 214 reports underwent detailed review; 2 misclassified cases were subsequently excluded.
The 214 neurologic VAERS reports included 111 DHHS and 103 DoD vaccinees: 105 (49%) were women, 106 (50%) were men, and sex was not identified for 3; overall, 17% of vaccinees were women. 16 One hundred seventy-two (80%) reports were for persons younger than 50 years; the 18-to 29-year group had the largest proportion of adverse events (66; 31%). One hundred thirteen (53%) were reported primary vaccinees. Of reported neurologic adverse events, 54% occurred within 1 week of vaccination and 86% occurred within 30 days. A number of clinical syndromes, including dizziness or vertigo, limb weakness, syncope, and paresthesias, were poorly defined and unassociated with shortterm morbidity and will not be discussed herein.
Headache, the predominant symptom among 44% of reports (TABLE 2), was most common and often accompanied by fever, chills, and fatigue. Most headache cases had no other evidence of neurologic dysfunction and had favorable outcome. Headaches requiring hospitalization and categorized as serious have been described. 18 A total of 39 serious neurologic adverse events associated with smallpox vaccination were reported to VAERS; 27 (69%) were among primary vaccinees and all but 2 occurred within 12 days of vaccination (TABLE 3) .
We classified 13 cases as suspected meningitis, defined by the presence of headache and lumbar puncture performance, indicative of warranting cerebrospinal fluid (CSF) examination. Of these 13, 1 had a documented pleocytosis, and 1 was reported as having CSF "consistent with meningitis," without further data. The remaining 11 reported normal or negative CSF or other study results (eg, head computed tomography, brain magnetic resonance imaging [MRI] ). No reports of meningitis occurred more than 14 days after vaccination. Eight (62%) were primary vaccinees.
We initially classified 4 cases as suspected encephalitis or myelitis, including the 2 cases on which SVAEMRA consulted and 2 identified through VAERS review alone. One report of transverse myelitis described normal CSF and onset 61 to 120 days following vaccination and was excluded. Of the remaining 3 cases, one man had probable encephalitis defined by altered mental status, pleocytosis, and multifocal demyelinating lesions on brain MRI 10 days after primary vaccination. Another man with suspected encephalitis developed fever, altered mental status, and pleocytosis 8 days after primary smallpox vaccination and several weeks after multiple other vaccinations; he recovered completely within 8 days. Cerebrospinal fluid polymerase chain reaction testing of both patients for vaccinia nucleic acid by the CDC's Poxvirus Laboratory was negative. A third patient with suspected encephalitis 7 days after primary vaccination had mental "slowing" that resolved completely in 1 day; Bell palsy (facial weakness) was reported in 11 vaccinees. The median interval between vaccination and reported onset was 7 days (range, 3-8 days). Six (55%) were primary vaccinees. We estimate the rate of reported Bell palsy to be 1.7 per 100 000 vaccinations (0.9/100 000 primary vaccinations).
Eight patients had reported seizures 9 days after vaccination. Seven (88%) were primary vaccinees. Three (38%) had a history of seizures. Among the remaining 5, 1 patient's seizure was attributed to hypoglycemia. Two had apparent new-onset seizures: neuroimaging, electroencephalography (EEG), and CSF analysis results were normal, and no recurrences were experienced 2 months after onset for one patient and 4 months for the other. The 2 remaining cases included one with apparent new-onset seizures with no EEG or MRI findings reported and another for whom seizures occurred in a clinical context of severe respiratory distress, cardiac abnormalities, and ultimately death. This case was reported in detail by a Sentinel Review process of the SVS WG and other DHHS entities 19 ; the suspected underlying etiology was a new-onset autoimmune syndrome.
GBS was reported twice in primary vaccinees and once in a revaccinee. The referring physicians attributed 2 cases to other concomitantly administered vaccinations; the interval between these vaccinations and onset was not reported. One individual for whom neurologic examination, CSF, or EMG findings were not available had GBS onset 1 day after vaccination, an interval biologically unlikely to reflect vaccine causality. Presuming all 3 temporal associations are valid and these cases were not misclassified, the maximum observed rate of GBS was 0.5 cases per 100 000 vaccinations.
COMMENT
Vaccines have reduced neurologic morbidity and mortality from many infections. [20] [21] [22] However, vaccines, including smallpox vaccine, carry a risk of adverse reactions, including rare severe neurologic syndromes. [23] [24] [25] Historically, PVE was the most frequent severe neurologic adverse event associated with smallpox vaccination. Estimated PVE rates vary significantly among studies, presumably because of differences in case definitions, variability in completeness of ascertainment and clinical evaluation, and differences among vaccine strains. An assessment of PVE in the United Kingdom between 1951 and 1960 found a reporting rate of 14 cases per million vaccinations. 25 Assessments in Germany in the 1940s and 1950s determined rates ranging from 121 to 449 per million vaccinations. [26] [27] [28] Studies done in the United States in the 1960s suggest a relative infrequency (9-51 cases/million vaccinations) but apparent severity of PVE, with 53% of 68 smallpox vaccine-associated deaths between 1959 and 1966 attributed to PVE. 1, 2, 4 The case-fatality rate for PVE was approximately 25%. 4 The rate and severity varied with the vaccinia strain, with certain reactogenic, neurotropic strains associated with higher rates. [29] [30] [31] Historically, PVE has been nearly 10-fold more common after primary vaccinations than revaccinations. 32 Clinicohistopathologic assessments in the 1920s and 1960s identified 2 clinicopathologic manifestations: microglial encephalitis and postvaccinial encephalopathy. 6, [33] [34] [35] Microglial encephalitis was more frequent in persons older than 2 years, occurred 10 to 20 days after vaccination, and was characterized by fever, vomiting, headache, and malaise, followed by decreased consciousness, seizures, and coma. Neuropathologically, these persons had widespread demyelination of subcortical white matter. Postvaccinial encephalopathy occurred mainly in children younger than 2 years at 6 to 12 days after vaccination and presented as fulminant seizures, hemiplegia, and elevated intracranial pressure. These patients had diffuse cerebral edema, lymphocytic meningeal infiltration, and perivascular hemorrhages. Vaccinial viremia and virus isolation from brain or CSF was sometimes detected. 36, 37 Although clinicopathologic correlates of PVE during the era of modern neuroimaging and neuroimmunology have not been possible, the demyelinating form of PVE probably corresponds to acute disseminated encephalomyelitis (ADEM) or postvaccination encephalomyelitis, whereas the cytotoxic form may represent an acute neuroinvasive vaccinial encephalomyelitis.
We identified 3 persons with probable or suspected encephalitis after smallpox vaccination, with cerebral inflammation evidenced by altered mental status and pleocytosis. One patient had a longer interval between vaccination and illness onset and MRI findings suggestive of ADEM, and the other 2 had features more consistent with acute viral encephalitis, including a shorter interval between vaccination and onset and rapid recovery. Our estimated reporting rate of probable or suspected PVE cases of 5 cases per million vaccinees is consistent with previous assessments conducted in the United States. Wide availability of neuroimaging and CSF examination allow distinction between mild neurologic symptoms and true cerebral inflammation, reducing misclassification of encephalitis. None of the persons in this study with suspected encephalitis died, perhaps because of improved supportive neurocritical care.
Aseptic meningitis was reported in 13 patients. However, only 2 demonstrated pleocytosis, suggesting that aseptic meningitis may have been overdiagnosed in earlier studies.
Bell palsy and GBS have been reported after infections and immunizations. Most population-based assessments have not found higher-thanexpected rates of these phenomena after vaccination, but a statistically significant association has been made for Bell palsy after intranasal influenza vaccine and hepatitis B vaccination 38, 39 and for GBS after rabies vaccination and some formulations of influenza vaccine. 40, 41 However, specific antecedent events are not usually evident. The expected rate of Bell palsy among the general population ranges between 15 and 40 cases per100 000 per year. 42, 43 The 11 cases of Bell palsy yields a rate of 1.7 per 100 000 vaccinations, about or lower than the expected incidence. Published estimates of GBS among the general population range from 0.4 to 4.0 cases per 100 000 per year. 44 The 3 cases of suspected GBS (estimated reporting rate of 0.5/100 000 vaccinations) is much lower than that observed within the general population. Further, 1 case of GBS was reported 1 day after vaccination, which suggests it was misclassified because a biological link with vaccination would be implausible.
Our estimations of the occurrences of GBS, Bell palsy, and PVE per number of vaccinations are ratios of reported events compared with the number of vaccinations. They are not expressed relative to units of time and are not directly comparable to the published populationbased incidence rates. Although not statistically valid, comparison of these ratios with known background rates may be a useful indicator of adverse-events trends associated with vaccinations. 45, 46 Overall, 69% of the serious neurologic adverse events, including all 3 cases of encephalitis, occurred among primary vaccinees, which is consistent with historical data describing more adverse events among primary vaccinees than among revaccinees.
Our assessment has limitations. Like all passive surveillance systems, VAERS reports are subject to underreporting, ascertainment bias and differential reporting, and variability in report quality and completeness. 46 We did not attempt to obtain additional information from medical record reviews beyond the 12 cases prospectively identified through clinical consultation. Some military personnel receive multiple vaccinations, making it difficult to associate any one with the presumed adverse event. Data on intercurrent infections in cases of suspected meningitis and encephalitis were not available.
Our findings identified many milder neurologic adverse events temporally but not necessarily causally associated with smallpox vaccination. They suggest that such events are generally selflimited, nonserious, and not associated with severe morbidity or mortality when screening defers persons with high-risk conditions. Smallpox vaccine is given to healthy people, which creates a low tolerance for associated risk. Risks associated with vaccines are best identified through population-based assessments. 47, 48 New, possibly less reactogenic smallpox vaccines are currently under development. Continued monitoring for neurologic events is needed to assess the safety of smallpox vaccines and to better characterize the spectrum of neurologic illness associated with them. als; state, territorial, county, city, and local health department professionals; and the civilian response team and monitoring activity volunteers. We thank Claudia Chesley, BA, for review and editing of the manuscript.
That approach leaves several critical issues unresolved. First, federal policy actively discourages high-quality research by making access to marijuana by researchers exceedingly difficult. Even when access to marijuana is finally granted, there is substantial variability in the purity and content of the product. Second, researchers need to test the assumption noted by Das that THC is the active ingredient responsible for the perceived beneficial effects. Although that assumption is reasonable, there remains the possibility that marijuana, not THC in isolation, achieves the desirable effects. Third, researchers should test the most efficient delivery system. There may be some added value in smoking that needs to be evaluated.
If research concludes that THC is the beneficial ingredient and that delivery by tablet is safest and most effective, then there is justification for approval of that method only. A synthetic THC oral medication (dronabinol) is already available for prescription with US Food and Drug Administration-approved indications for anorexia associated with weight loss in patients with AIDS and for nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.
Regulation of the use of marijuana for medical purposes is feasible and socially desirable, but it will require a different way of thinking about the problem. It requires viewing marijuana as a potential medication subject to carefully controlled research, rather than as a drug of strict prohibition. blood pressure regulation and provides the basis for targeting research to the stimulation of endogenous nitric oxide synthesis as a novel blood pressure-lowering principle.
